SCHEMBL4639713

SCHEMBL4639713

N#Cc1ccc(NS(=O)(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.66
CA2 P00918 3/20 0.66
KDM1A O60341 1/20 0.53
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
SLC22A12 Q96S37 1/20 0.47
CYP19A1 P11511 1/20 0.47
MMP2 P08253 1/20 0.47
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
TSHR P16473 1/20 0.46
NLRP3 Q96P20 1/20 0.46
IDO1 P14902 2/20 0.45
SAE1 Q9UBE0 1/20 0.44
UBA2 Q9UBT2 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455223 0.82 PTPRB (0.48) CA1CA2CA12CA9LMNA
SCHEMBL3793259 0.81 CA1 (0.42) CA1CA2KDM1ACA12CA9
SCHEMBL3366734 0.79 CA1 (0.66) CA1CA2KDM1ACA12CA9
SCHEMBL1646278 0.79 CA1 (1.00) CA1CA2KDM1ACA12CA9
SCHEMBL4959361 0.79 CA1 (0.66) CA1CA2KDM1ACA12CA9
SCHEMBL27183273 0.78 CA1 (0.63) CA1CA2KDM1ACA12CA9
Sulfuric Acid SCHEMBL20984569 0.78 CA1 (0.58) CA1CA2KDM1ACA12CA9
SCHEMBL9529531 0.76 CA1 (0.56) CA1CA2KDM1ACA12CA9
SCHEMBL28549758 0.76 CA1 (0.61) CA1CA2KDM1ASLC22A12CYP19A1
SCHEMBL7863309 0.76 PTPRB (0.42) CA1CA2CA12CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands NOVARTIS AG (CH) 2008-12-11 US disclosed
EP-1893591-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS Novartis AG (CH) 2008-03-05 EP disclosed
WO-2006131336-A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS NOVARTIS AG (CH) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306124-A1 Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands SOX18, SIGMAR1, SUCNR1 CA1 1379/4885CA2 1053/4885KDM1A 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.